CD4 and cervical cancer: Patients with recurrent cervical cancers showed significant 2.2‐fold higher amounts of Th17 cells per CD4+ T cells after therapy in their blood (median 13.89%; P = 0.0009) in comparison with patients without relapse (median 6.2%; Fig. 5A) regardless whether they were treated with aCRT (circles) or pCRT (triangles).